Evaluation and Review of Strategies to Assess Cardiovascular Risk in Clinical Trials in Patients with Type 2 Diabetes Mellitus

Statistics in Biopharmaceutical Research

Volumn 7, Issue 4, 2015, Pages 253-266

  Marchenko, Olga ^a   Jiang, Qi ^c   Chakravarty, Aloka ^b   Ke, Chunlei ^c   Ma, Haijun ^c   Maca, Jeff ^a   Russek Cohen, Estelle ^b   Sanchez Kam, Matilde ^d   C Zink, Richard ^e,f   Chuang Stein, Christy ^g  

^a IQVIA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c AMGEN INC   (United States)

^d Arena Pharmaceuticals   (United States)

^e SAS INSTITUTE INC   (United States)

^f University of North Carolina at Chapel Hill   (United States)

^g PFIZER INC   (United States)

Author keywords

Cardiovascular risk; CVOT; Diabetes mellitus; Meta analysis; Trial design

Indexed keywords

ALOGLIPTIN; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; INSULIN DETEMIR; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN;

ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG SAFETY; DRUG SCREENING; EDUCATION PROGRAM; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 84950308481     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2015.1077724     Document Type: Article

References (15)

1. Committee for Medicinal Products for Human Use (CHMP) (2012), ``Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus,’’. available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
2. FDA Guidance to Industry (2008), ``Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes,’’ available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
3. FDA Guidance to Industry (DMC Guidance) (2006), ``Establishment and Operation of Clinical Trial Data Monitoring Committees,’’ available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf
4. M.J.Geiger,, C.Mehta,, J.R.Turner,, C.Arbet-Engels,, S.Hantel,, B.Hirshberg,, J.Koglin,, B.Mendzelevski,, P.T.Sager,, D.Shapiro,, M.Stewart,, T.G.Todaro,, and B.Gaydos, (2015), “Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes,” Therapeutic Innovation and Regulatory Science, 49, 50–64.
5. J.B.Green,, M.A.Bethel,, S.K.Paul,, A.Ring,, K.D.Kaufman,, D.R.Shapiro,, R.M.Califf,, and R.R.Holman, (2013), “Rationale, Design, and Organization of A Randomized, Controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in Patients With Type 2 Diabetes and Established Cardiovascular Disease,” American Heart Journal, 166, 983–989.
6. C.H.Hennekens,, and D.DeMets, (2009), “The Need for Large Scale Randomized Evidence Without Undue Emphasis on Small Trials, Their Metaanalyses or Subgroup Analyses,” The Journal of the American Medical Association, 302, 2361–2362.
7. D.C.Hoaglin,, N.Hawkins,, J.P.Jansen,, D.A.Scott,, R.Itzler,, J.C.Cappelleri,, C.Boersma,, D.Thompson,, K.M.Larholt,, M.Diaz,, and A.Barrett, (2011), “Conduct Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices—Part 2,” Value in Health, 14, 429–437.
8. P.D.Home,, S.J.Pocock,, H.Beck-Nielsen,, P.S.Curtis,, R.Gomis,, M.Hanefeld,, N.P.Jones,, M.Komajda,, J.J.McMurray, (2009), “Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): A Multicentre, Randomised, Open-Label Trial,” Lancet, 373, 2125–2135.
9. J.P.Jansen,, T.Trikalinos,, J.C.Cappelleri,, J.Daw,, S.Andes,, R.Eldessouki,, and G.Salanti, (2014), “Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: An ISPOR-AMCP-NPC Good Practice Task Force Report,” Value in Health, 17, 157–173.
10. J.P.Jansen,, R.Fleurence,, B.Devine,, R.Itzler,, A.Barrett,, N.Hawkins,, K.Lee,, C.Boersma,, L.Annemans,, and J.C.Cappelleri, (2011), “Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making. Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part I,” Value in Health, 14, 417–428.
11. C.Jennison,, and B.W.Turnbull, (2000), Group Sequential Methods with Applications to Clinical Trials, Boca Raton, FL: Chapman & Hall.
12. D.Madigan,, P.B.Ryan,, and M.Schuemie,. “Does Design Matter? Systematic Evaluation of the Impact of Analytical Choices on Effect Estimates in Observational Studies,” Therapeutic Advances in Drug Safety, 4, 53–62.
13. S.E.Nissen,, and K.Wolski, (2007), “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death From Cardiovascular Causes,” The New England Journal of Medicine, 356, 2457–2471.
14. S.E.Nissen,, K.Wolski,, and E.J.Topol, (2005), “Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus,” The Journal of the American Medical Association, 294, 2581–2586.
15. L.Tian,, T.Cai,, M.A.Pfeffer,, N.Piankov,, P.Y.Cremieux,, and L.J.Wei, (2009), “Exact and Efficient Inference Procedure for Meta-Analysis and its Application to the Analysis of Independent 2×2 Tables with All Available Data but Without Artificial Continuity Correction,” Biostatistics, 10, 275–281.